Development and characterization of a human antibody reference panel against erythropoietin suitable for the standardization of ESA immunogenicity testing

Journal of Immunological Methods

Volumn 382, Issue 1-2, 2012, Pages 129-141

  Mytych, Daniel T ^a   Barger, Troy E ^a   King, Chadwick ^b   Grauer, Stephanie ^b   Haldankar, Raj ^a   Hsu, Eric ^a   Wu, Michelle Min ^a   Shiwalkar, Mukta ^a   Sanchez, Sergio ^a   Kuck, Andrew ^a   Civoli, Francesca ^a   Sun, Jilin ^a   Swanson, Steven J ^a  

^a AMGEN INC   (United States)

^b Amgen British Columbia ^*  (Canada)

Author keywords

Anti drug antibodies (ADAs); Antibody reference reagent; Erythropoiesis stimulating agents (ESAs); Erythropoietin; Immunogenicity; Pure red cell aplasia (PRCA)

Indexed keywords

ANTIANEMIC AGENT; EPITOPE; ERYTHROPOIETIN ANTIBODY; ERYTHROPOIETIN RECEPTOR; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN M; MICERA; NEUTRALIZING ANTIBODY; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; BINDING SITE; CROSS REACTION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERYTHROPOIETIN; HEMATINICS; HUMANS; MICE; MICE, TRANSGENIC; RECOMBINANT PROTEINS; REFERENCE STANDARDS; SENSITIVITY AND SPECIFICITY;

EID: 84863574656     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2012.05.013     Document Type: Article

References (37)

1. Babcook, J., Jia, Xiao-Chi, Kang, J.S., Zhang, Li, 2010. Identification of high affinity molecules by limited dilution screening. US Patent# 7,754,433.
2. Barger T.E., Kuck A.J., Chirmule N., Swanson S.J., Mytych D.T. Detection of anti-ESA antibodies in human samples from PRCA and non-PRCA patients: an immunoassay platform comparison. Nephrol. Dial. Transplant. 2011, 1.
3. Burgess T., Coxon A., Meyer S., Sun J., Rex K., Tsuruda T., Chen Q., Ho S.Y., Li L., Kaufman S., McDorman K., Cattley R.C., Sun J., Elliott G., Zhang K., Feng X., Jia X.C., Green L., Radinsky R., Kendall R. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-met-dependent human tumors. Cancer Res. 2006, 66:1721.
4. Buttel I.C., Voller K., Schneider C.K. Immunogenicity and its impact on benefit/risk considerations in the authorisation of biopharmaceuticals. Curr. Drug Saf. 2010, 5:287.
5. Casadevall N., Nataf J., Viron B., Kolta A., Kiladjian J.-J., Martin-Dupont P., Michaud P., Papo T., Ugo V., Teyssandier I., Varet B., Mayeux P. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. 2002, 346:469.
6. Cheetham J.C., Smith D.M., Aoki K.H., Stevenson J.L., Hoeffel T.J., Syed R.S., Egrie J., Harvey T.S. NMR structure of human erythropoietin and a comparison with its receptor bound conformation. Nat. Struct. Biol. 1998, 5:861.
7. Deechongkit S., Aoki K.H., Park S.S., Kerwin B.A. Biophysical comparability of the same protein from different manufacturers: a case study using Epoetin alfa from Epogen® and Eprex®. J. Pharm. Sci. 2006, 95:1931.
8. Durocher Y., Perret S., Kamen A. High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res. 2002, 30:e9.
9. Elliott S., Lorenzini T., Chang D., Barzilay J., Delorme E. Mapping of the active site of recombinant human erythropoietin. Blood 1997, 89:493.
10. Epogen® (Epoetin alfa) Prescribing Information. Amgen Inc., Thousand Oaks, CA (v25 06/2011).
11. Erslev A.J. Erythropoietin. N. Engl. J. Med. 1991, 324:1339.
12. Haldankar R., Li D., Saremi Z., Baikalov C., Deshpande R. Serum-free suspension large-scale transient transfection of CHO cells in WAVE bioreactors. Mol. Biotechnol. 2006, 34:191.
13. Hoesel W., Gross J., Moller R., Kanne B., Wessner A., Müller G., Müller A., Gromnica-Ihle E., Fromme M., Bischoff S., Haselbeck A. Development and evaluation of a new ELISA for the detection and quantification of antierythropoietin antibodies in human sera. J. Immunol. Methods 2004, 294:101.
14. Johnsson B., Lofas S., Lindquist G. Immobilization of proteins to a carboxymethyldextran-modified gold surface for biospecific interaction analysis in surface plasmon resonance sensors. Anal. Biochem. 1991, 198:268.
15. Keithi-Reddy S.R., Kandasamy S., Singh A.K. Pure red cell aplasia due to follow-on epoetin. Kidney Int. 2008, 74:1617.
16. Kellerman S.A., Green L.L. Antibody discovery: the use of transgenic mice to generate human monoclonal antibodies for therapeutics. Curr. Opin. Biotechnol. 2002, 13:593.
17. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256(5517):495-497.
18. Lin F.K., Suggs S., Lin C.H., Browne J.K., Smalling R., Egrie J.C., Chen K.K., Fox G.M., Martin F., Stabinsky Z. Cloning and expression of the human erythropoietin gene. Proc. Natl. Acad. Sci. U. S. A. 1985, 82:7580.
19. Mendez M.J., Green L.L., Corvalan J.R., Jia X.-C., Maynard-Currie C.E., Yang X.-D., et al. Functional transplant of megabase human immunoglobulin loci recapulates human antibody response in mice. Nat. Genet. 1997, 15:146.
20. Mytych D.T., La S., Barger T., Ferbas J., Swanson S.J. The development and validation of a sensitive, dual-flow cell, SPR-based biosensor immunoassay for the detection, semi-quantitation, and characterization of antibodies to darbepoetin alfa and epoetin alfa in human serum. J. Pharm. Biomed. Anal. 2009, 49:415.
21. Philo J.S., Aoki K.H., Arakawa T., Narhi L.O., Wen J. Dimerization of the extracellular domain of the erythropoietin (EPO) Receptor by EPO: one high-affinity and one low-affinity interaction. Biochemistry 1996, 35:1681.
22. Pollock C., Johnson D.W., Hörl W.H., Rossert J., Casadevall N., Schellekens H., Delage R., De Francisco A., Macdougall I., Thorpe R., Toffelmire E. Pure red cell aplasia induced by erythropoiesis-stimulating agents. Clin. J. Am. Soc. Nephrol. 2008, 3:193.
23. Praditpornsilpa K., Tiranathanagul K., Kupatawintu P., Jootar S., Intragumtornchai T., Tungsanga K., Teerapornlertratt T., Lumlertkul D., Townamchai N., Susantitaphong P., Katavetin P., Kanjanabuch T., Avihingsanon Y., Eiam-Ong S. Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies. Kidney Int. 2011, 80:88. Epub Mar 23. 10.1038/ki.2011.68.
24. Purves W.K., Sadava D., Orians G.H., Heller H.C. Life:The Science of Biology 2001, Sinauer Associates, Sunderland, M.A. and Freeman, W.H., New York, NY. 6th ed.
25. Rosenberg A. Effects of protein aggregates: an immunologic perspective. AAPS J. 2006, 8:E501.
26. Ryan M.H., Heavner G.A., Brigham-Burke M., McMahon F., Shanahan M.F., Gunturi S.R., Sharma B., Farrell F.X. An in vivo model to assess factors that may stimulate the generation of an immune reaction to erythropoietin. Int. Immunopharmacol. 2006, 6:647.
27. Säfsten P., Klakamp S.L., Drake A.W., Karlsson R., Myszka D.G. Screening antibody-antigen interactions in parallel using Biacore A100. Anal. Biochem. 2006, 353:181.
28. Schellekens H. Factors influencing the immunogenicity of therapeutic proteins. Nephrol. Dial. Transplant. 2005, 20:vi3.
29. Schellekens H. How to predict and prevent the immunogenicity of therapeutic proteins. Biotechnol. Annu. Rev. 2008, 14:191.
30. Sułowicz W., Bentkowski W., Stompór T., Gross J., Biłyk A., Rudzki Z. Pure red cell aplasia due to treatment with epoietin beta: first case report of PRCA from Poland. Przegl. Lek. 2006, 63:810.
31. Swanson S.J., Ferbas J., Mayeux P., Casadevall N. Evaluation of methods to detect and characterize antibodies against recombinant human erythropoietin. Nephron Clin. Pract. 2004, 96:c88.
32. Syed R.S., Reid S.W., Li C., Cheetham J.C., Aoki K.H., Liu B., Zhan H., Osslund T.D., Chirino A.J., Zhang J., Finer-Moore J., Elliott S., Sitney K., Katz B.A., Matthews D.J., Wendoloski J.J., Egrie J., Stroud R.M. Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature 1998, 395:511.
33. Tacey R., Greway A., Smiell J., Power D., Kromminga A., Daha M., Casadevall N., Kelley M. The detection of anti-erythropoietin antibodies in human serum and plasma: part I. Validation of the protocol for a radioimmunoprecipitation assay. J. Immunol. Methods 2003, 283:317.
34. Thorpe R., Swanson S.J. Current methods for detecting antibodies against erythropoietin and other recombinant proteins. Clin. Diagn. Lab. Immunol. 2005, 12:28.
35. van Beers M.M.C., Jiskoot W., Schellekens H. On the role of aggregates in the immunogenicity of recombinant human interferon beta in patients with multiple sclerosis. J. Interferon Cytokine Res. 2010, 30:767.
36. Wei X., Swanson S.J., Gupta S. Development and validation of a cell-based bioassay for the detection of neutralizing antibodies against recombinant human erythropoietin in clinical studies. J. Immunol. Methods 2004, 293:115.
37. Wen J., Jiang Y., Narhi L. Applications of DSC for antibodies and Fc-conjugated proteins. Am. Pharm. Rev. 2007, 10:10.